Table 3.
Summary of the published base case cost-effectiveness studies of bortezomib or bortezomib-contained regimens for multiple myeloma (ICER was adjusted by 2014 country-specific GDPPC)
| Treatment setting | Comparison | Included studies | Country | Adjusted ICER by 2014 GDPPC |
|---|---|---|---|---|
| Induction treatment prior to SCT | BTZ-containing regimen versus non-BTZ treatment | Kouroukis et al12 | Canada | 2.2544/QALY |
| VD versus CTD | Mucha et al13 | Poland | 1.2584/QALY | |
| VD versus VAD | Mucha et al13 | Poland | 1.0083/QALY | |
| VTD versus CTD | Mucha et al13 | Poland | 0.5588/QALY | |
| VTD versus TD | Mucha et al13 | Poland | 0.9864/QALY | |
| Van Beurden-Tan et al14 | Germany | 0.9299/QALY | ||
| Previously untreated MM but ineligible for SCT | VMP versus MP | Yoong et al19 | Canada | 1.1060/QALY |
| Garrison Jr et al16 | USA | 1.1622/QALY | ||
| Picot et al18 | UK | 1.2070/QALY | ||
| Rickert et al15 | Sweden | 2.3744/QALY | ||
| Oster et al17 | USA | 2.0059/QALY | ||
| VMP versus MPT | Rickert et al15 | Sweden | 2.0248/QALY | |
| Garrison Jr et al16 | USA | Dominant | ||
| Yoong et al19 | Canada | 0.7323/QALY | ||
| Picot et al18 | UK | Dominated | ||
| VMP versus MPR-R | Garrison Jr et al16 | USA | Dominant | |
| Oster et al17 | USA | 1.3979/QALY (MPR-R versus VMP) | ||
| VMP versus CTD | Picot et al18 | UK | 1.1911/QALY | |
| VMP versus RD | Cavenagh et al20 | USA | 1.5775/QALY (RD versus VMP) | |
| Relapsed/refractory MM | BTZ versus BSC | Bagust et al21 | UK | 0.9317–1.8210/LY |
| Mehta et al22 | USA | 1.0933/LY | ||
| Mehta et al22 | USA | 1.2004/LY | ||
| BTZ versus THD | Mehta et al22 | USA | 0.5178/QALY | |
| BTZ versus DEX | Hornberger et al25 | Sweden | 3.2062/QALY | |
| Liwing et al27 | Nordic countries | €54451–€81560/QALY | ||
| BTZ versus LEN/DEX | Felix et al23 | Portugal | 2.5532–3.0187/QALY (LEN/DEX versus BTZ) | |
| Fragoulakis et al24 | Greece | 2.0259/QALY (LEN/DEX versus BTZ) | ||
| Hornberger et al25 | Sweden | Dominant | ||
| Jiang et al26 | UK | Dominant | ||
| Liwing et al27 | Nordic countries | Dominant | ||
| Moller et al28 | Norway | 0.5205/QALY (LEN/DEX versus BTZ) |
Abbreviations: BSC, best supportive care; BTZ, bortezomib; CTD, cyclophosphamide/thalidomide/dexamethasone; DEX, dexamethasone; GDPPC, gross domestic product per capita; ICER, incremental cost-effectiveness ratio; LEN, lenalidomide; MM, multiple myeloma; MP: melphalan/prednisone; MPR-R, melphalan/prednisone/lenalidomide with lenalidomide maintenance; MPT, melphalan/prednisone/thalidomide; RD, lenalidomide plus low-dose dexamethasone; SCT, stem cell transplantation; THD, thalidomide; TD, thalidomide/dexamethasone; VD, bortezomib/dexamethasone; VAD, vincristine/adriamycin/dexamethasone; VMP, bortezomib/melphalan/prednisone; VTD, bortezomib/thalidomide/dexamethasone.